Overview

BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer

Status:
Completed
Trial end date:
2017-08-15
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if knowing biomarker status can help researchers find better treatment combinations for patients with advanced NSCLC. Researchers want to use biomarker status to decide what drug (bevacizumab, or cixutumumab) to give in combination with carboplatin and pemetrexed. The safety of these drug combinations will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Eli Lilly and Company
Genentech, Inc.
ImClone LLC
Treatments:
Antibodies
Antibodies, Monoclonal
Bevacizumab
Carboplatin
Folic Acid Antagonists
Pemetrexed